Zhuo Mao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Zhuo Mao has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
- Weizhen Zhang
School of Basic Medical Science, Peking University, Beijing 100191, China
5 shared publications Ke Pan
School of Basic Medical Sciences, Shenzhen University Medical Center, Shenzhen University Health Science Center, Shenzhen, China
3 shared publicationsMingji Feng
School of Basic Medical Sciences, Shenzhen University Medical Center, Shenzhen University Health Science Center, Shenzhen, China
3 shared publicationsWen Su
School of Basic Medical Sciences, Shenzhen University Medical Center, Shenzhen University Health Science Center, Shenzhen, China
2 shared publicationsBingfeng Li
1 shared publicationChao Lv
1 shared publication
Latest Publications
- 23 September 2026
- Published by Elsevier in Molecular and Cellular Endocrinology
- Vol. 623
Impaired FXR-syntaxin 1A pathway contributes to diabetic β-cell secretory dysfunction
- 23 September 2026
- Published by Elsevier in Molecular and Cellular Endocrinology
- Vol. 623
Impaired FXR-syntaxin 1A pathway contributes to diabetic β-cell secretory dysfunction
- Open Access
- 3 August 2021
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 12, 721471
ZnT8 Deficiency Protects From APAP-Induced Acute Liver Injury by Reducing Oxidative Stress Through Upregulating Hepatic Zinc and Metallothioneins
Zinc transporter 8 (ZnT8) is an important zinc transporter highly expressed in pancreatic islets. Deficiency of ZnT8 leads to a marked decrease in islet zinc, which is thought to prevent liver diseases associated with oxidative stress. Herein, we aimed to investigate whether loss of islet zinc affects the antioxidant capacity of the liver and acute drug-induced liver injury. To address this question, we treated ZnT8 knockout (KO) or wild-type control mice with 300 mg/ kg acetaminophen (APAP) or phosphate-buffered saline (PBS). Unexpectedly, we found that loss of ZnT8 in mice ameliorated APAP-induced injury and was accompanied by inhibition of c-Jun N-terminal kinase (JNK) activation, reduced hepatocyte death, and decreased serum levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST). An increase in hepatic glutathione (GSH) was observed, corresponding to a decrease in malondialdehyde (MDA) and 4-hydroxynonenal (4-HNE) levels. APAP-induced inflammation and glycogen depletion were alleviated. In contrast, no significant changes were observed in cytochrome P450 family 2 subfamily E member 1 (CYP2E1), the main enzyme responsible for drug metabolism. Elevated levels of hepatic zinc and metallothionein (MT) were also observed, which may contribute to the hepatoprotective effect in ZnT8 KO mice. Taken together, these results suggest that ZnT8 deficiency protects the liver from APAP toxicity by attenuating oxidative stress and promoting hepatocyte proliferation. This study provides new insights into the functions of ZnT8 and zinc as key mediators linking pancreatic and hepatic functions.
- 3 August 2021
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 12, 721471
Open AccessZnT8 Deficiency Protects From APAP-Induced Acute Liver Injury by Reducing Oxidative Stress Through Upregulating Hepatic Zinc and Metallothioneins
Zinc transporter 8 (ZnT8) is an important zinc transporter highly expressed in pancreatic islets. Deficiency of ZnT8 leads to a marked decrease in islet zinc, which is thought to prevent liver diseases associated with oxidative stress. Herein, we aimed to investigate whether loss of islet zinc affects the antioxidant capacity of the liver and acute drug-induced liver injury. To address this question, we treated ZnT8 knockout (KO) or wild-type control mice with 300 mg/ kg acetaminophen (APAP) or phosphate-buffered saline (PBS). Unexpectedly, we found that loss of ZnT8 in mice ameliorated APAP-induced injury and was accompanied by inhibition of c-Jun N-terminal kinase (JNK) activation, reduced hepatocyte death, and decreased serum levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST). An increase in hepatic glutathione (GSH) was observed, corresponding to a decrease in malondialdehyde (MDA) and 4-hydroxynonenal (4-HNE) levels. APAP-induced inflammation and glycogen depletion were alleviated. In contrast, no significant changes were observed in cytochrome P450 family 2 subfamily E member 1 (CYP2E1), the main enzyme responsible for drug metabolism. Elevated levels of hepatic zinc and metallothionein (MT) were also observed, which may contribute to the hepatoprotective effect in ZnT8 KO mice. Taken together, these results suggest that ZnT8 deficiency protects the liver from APAP toxicity by attenuating oxidative stress and promoting hepatocyte proliferation. This study provides new insights into the functions of ZnT8 and zinc as key mediators linking pancreatic and hepatic functions.
- 22 October 2020
- Published by American Diabetes Association in Diabetes
- Vol. 70 (1) , 214-226
ETV5 Regulates Hepatic Fatty Acid Metabolism Through PPAR Signaling Pathway
ETV5 is an ETS transcription factor that has been associated with obesity in genomic association studies. However, little is known about the role of ETV5 in hepatic lipid metabolism and nonalcoholic fatty liver disease. In the current study, we found that ETV5 protein expression was increased in diet- and genetically induced steatotic liver. ETV5 responded to the nutrient status in a mammalian target of rapamycin complex 1 (mTORC1)–dependent manner and in turn, regulated mTORC1 activity. Both viral-mediated and genetic depletion of ETV5 in mice led to increased lipid accumulation in the liver. RNA sequencing analysis revealed that peroxisome proliferator–activated receptor (PPAR) signaling and fatty acid degradation/metabolism pathways were significantly downregulated in ETV5-deficient hepatocytes in vivo and in vitro. Mechanistically, ETV5 could bind to the PPAR response element region of downstream genes and enhance its transactivity. Collectively, our study identifies ETV5 as a novel transcription factor for the regulation of hepatic fatty acid metabolism, which is required for the optimal β-oxidation process. ETV5 may provide a therapeutic target for the treatment of hepatic steatosis.
- 22 October 2020
- Published by American Diabetes Association in Diabetes
- Vol. 70 (1) , 214-226
ETV5 Regulates Hepatic Fatty Acid Metabolism Through PPAR Signaling Pathway
ETV5 is an ETS transcription factor that has been associated with obesity in genomic association studies. However, little is known about the role of ETV5 in hepatic lipid metabolism and nonalcoholic fatty liver disease. In the current study, we found that ETV5 protein expression was increased in diet- and genetically induced steatotic liver. ETV5 responded to the nutrient status in a mammalian target of rapamycin complex 1 (mTORC1)–dependent manner and in turn, regulated mTORC1 activity. Both viral-mediated and genetic depletion of ETV5 in mice led to increased lipid accumulation in the liver. RNA sequencing analysis revealed that peroxisome proliferator–activated receptor (PPAR) signaling and fatty acid degradation/metabolism pathways were significantly downregulated in ETV5-deficient hepatocytes in vivo and in vitro. Mechanistically, ETV5 could bind to the PPAR response element region of downstream genes and enhance its transactivity. Collectively, our study identifies ETV5 as a novel transcription factor for the regulation of hepatic fatty acid metabolism, which is required for the optimal β-oxidation process. ETV5 may provide a therapeutic target for the treatment of hepatic steatosis.
- 1 April 2019
- Published by Elsevier in Molecular and Cellular Endocrinology
- Vol. 485, 72-80
ETV5 regulates GOAT/ghrelin system in an mTORC1-dependent manner
- 1 April 2019
- Published by Elsevier in Molecular and Cellular Endocrinology
- Vol. 485, 72-80
ETV5 regulates GOAT/ghrelin system in an mTORC1-dependent manner
- Open Access
- 8 August 2018
- Published by IntechOpen
Hormonal Regulation of Cholesterol Homeostasis
Cholesterol homeostasis is tightly regulated by a group of endocrine hormones under physiological conditions. Hormonal dysregulation is often associated with disturbed cholesterol homeostasis, resulting in many clinical disorders including atherosclerosis, fatty liver and metabolic syndrome. Circulating hormones regulate cholesterol metabolism by altering levels of relative genes either through their interactions with nuclear receptors or by interfering with bile acid signaling pathways. A better understanding of hormonal regulation of cholesterol metabolism would improve our likelihood of identifying effective and selective targets for the intervention of disturbed cholesterol. In this review, we discuss selected hormones critical for the cholesterol balance, including thyroid hormone, sex hormones, growth hormone, glucagon and irisin. We focus our discussion on the most recent advance in clinical epidemiology, animal mechanistic studies and the clinical application.
- 8 August 2018
- Published by IntechOpen
Open AccessHormonal Regulation of Cholesterol Homeostasis
Cholesterol homeostasis is tightly regulated by a group of endocrine hormones under physiological conditions. Hormonal dysregulation is often associated with disturbed cholesterol homeostasis, resulting in many clinical disorders including atherosclerosis, fatty liver and metabolic syndrome. Circulating hormones regulate cholesterol metabolism by altering levels of relative genes either through their interactions with nuclear receptors or by interfering with bile acid signaling pathways. A better understanding of hormonal regulation of cholesterol metabolism would improve our likelihood of identifying effective and selective targets for the intervention of disturbed cholesterol. In this review, we discuss selected hormones critical for the cholesterol balance, including thyroid hormone, sex hormones, growth hormone, glucagon and irisin. We focus our discussion on the most recent advance in clinical epidemiology, animal mechanistic studies and the clinical application.
- Top Cited PapersOpen Access
- 13 July 2018
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 19 (7) , 2043
Role of mTOR in Glucose and Lipid Metabolism
The mammalian target of rapamycin, mTOR is the master regulator of a cell’s growth and metabolic state in response to nutrients, growth factors and many extracellular cues. Its dysregulation leads to a number of metabolic pathological conditions, including obesity and type 2 diabetes. Here, we review recent findings on the role of mTOR in major metabolic organs, such as adipose tissues, liver, muscle, pancreas and brain. And their potentials as the mTOR related pharmacological targets will be also discussed.
- 13 July 2018
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 19 (7) , 2043
Top Cited PapersOpen AccessRole of mTOR in Glucose and Lipid Metabolism
The mammalian target of rapamycin, mTOR is the master regulator of a cell’s growth and metabolic state in response to nutrients, growth factors and many extracellular cues. Its dysregulation leads to a number of metabolic pathological conditions, including obesity and type 2 diabetes. Here, we review recent findings on the role of mTOR in major metabolic organs, such as adipose tissues, liver, muscle, pancreas and brain. And their potentials as the mTOR related pharmacological targets will be also discussed.
- Open Access
- 19 July 2017
- Published by IntechOpen
Neuroendocrine Control of Hepatic Gluconeogenesis
Glucose is intricately regulated in human body through a complex network of hormonal and neuronal factors. A series of evidence suggests that the gastrointestinal tract and the central nervous system play prominent roles in the regulation of glucose and energy homeostasis. The gut senses the nutrient supply to coordinate the release of hormones that activate neuronal networks in the brain, leading to the subsequent modulation of hepatic glucose output via the gut-brain-liver axis. The gut hormones also act on multiple peripheral tissues to regulate glucose level through an insulindependent and/or-independent mechanism. The brain, especially the hypothalamus, could also response to the hormones such as insulin and leptin and different nutrients to modulate the glucose homeostasis. In this chapter, we review the gut-brainliver axis and the role of this organ interaction in the control of glucose homeostasis. A better understanding of these pathways will provide novel strategies for improved glycaemic control.
- 19 July 2017
- Published by IntechOpen
Open AccessNeuroendocrine Control of Hepatic Gluconeogenesis
Glucose is intricately regulated in human body through a complex network of hormonal and neuronal factors. A series of evidence suggests that the gastrointestinal tract and the central nervous system play prominent roles in the regulation of glucose and energy homeostasis. The gut senses the nutrient supply to coordinate the release of hormones that activate neuronal networks in the brain, leading to the subsequent modulation of hepatic glucose output via the gut-brain-liver axis. The gut hormones also act on multiple peripheral tissues to regulate glucose level through an insulindependent and/or-independent mechanism. The brain, especially the hypothalamus, could also response to the hormones such as insulin and leptin and different nutrients to modulate the glucose homeostasis. In this chapter, we review the gut-brainliver axis and the role of this organ interaction in the control of glucose homeostasis. A better understanding of these pathways will provide novel strategies for improved glycaemic control.